Loading data for PCRX — first visit, this takes a few seconds.

Pacira BioSciences Inc.

NasdaqGS: PCRX · Real-Time Price · USD
24.67
+0.84 (3.52%)
At close: Aug 24, 2026, 8:00 PM
24.86
+0.00%
After-hours: 5:31 PM

The price, the headline numbers and the latest news, in one place.

Pacira BioSciences Inc. (PCRX) Stock Price, Analysis & Data

3.52%

No data available

Bid17.59
Market Cap990.97M
Revenue (ttm)746.16M
Net Income (ttm)14.64M
0.27
0.35
71.03
7.21
P/B (ttm)1.47
P/S (ttm)1.31
Earnings DateNov 5, 2026
Ask30.59
Volume421,085
Avg. Volume (20D)551,837
Open23.91
Previous Close23.83
Day's Range23.66 - 24.72
52-Week Range18.80 - 27.66
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and kne...

Sector Healthcare
IPO Date Feb 3, 2011
Employees 825
Stock Exchange NasdaqGS
Ticker Symbol PCRX
Full Company Profile

Financial Performance

In 2025, Pacira BioSciences's revenue was 726.41M, an increase of 3.63% compared to the previous year's 700.97M. Earnings were 7.03M, a decrease of -107.07%.

Financial Statements

Earnings Surprise

Pacira BioSciences has released their quarterly earnings on Aug 4, 2026:
  • Revenue of $192.4M misses estimates by $0, with 6.24% YoY growth.
  • EPS of 0.73 exceeds estimates by 0.08, with -1.35% YoY decline.
Pacira BioSciences Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade